New drug tirzepatide improves sleep apnea, weight loss in trials

Tirzepatide, a new drug, significantly improved sleep apnea and weight loss in adults with obesity and moderate-to-severe obstructive sleep apnea. In two phase III trials, tirzepatide reduced apnea-hypopnea index, body weight, high-sensitivity C-reactive protein, hypoxic burden, and systolic blood pressure, while improving sleep-related outcomes. The trials had high completion rates and showed promising results, indicating tirzepatide's potential as a treatment for OSA and obesity.